Top Injectable Manufacturer in Israel – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 3 days ago
- 11 min read
Last Updated: August 23, 2026
TL;DR: Israel is one of the most demanding regulated markets an Indian sterile-injectable manufacturer can approach, and it is worth being direct about why. Medicines are registered by the Ministry of Health's Pharmaceutical Division under the Pharmacists Ordinance (New Version) 1981 and the Pharmacists Regulations (Preparations) 1986, with quality certification issued by the Institute for Standardization and Control of Pharmaceuticals (ISCP) in Jerusalem. A reform effective 23 March 2025 created three reliance-based fast tracks of 70 or 120 working days, but access depends on prior approval by the US FDA, EMA, UK MHRA, Health Canada, Swissmedic or Australia's TGA. India's CDSCO is not on that list, so a product approved only in India has no access to those tracks and falls onto the full national route with its statutory 270-day decision clock. Israel has been a PIC/S member since January 2009 and aligned its GMP standards, inspection procedures and forms to the EU under the EU-Israel ACAA in force since January 2013, so an overseas sterile site should expect EU-GMP or PIC/S-standard evidence rather than a WHO-GMP certificate alone. The registration holder must be an Israeli entity filing through a licensed Israeli pharmacist, with packaging in Hebrew and English and patient leaflets in Hebrew and Arabic. On the favourable side, Israel and India are both Apostille Convention parties with no objection between them, so Indian documents need only an MEA apostille. Demand is real: Israel passed 10 million people in January 2026, drug shortages rose 2.66-fold between 2014 and 2022, and oncology took 52% of the 2026 health basket expansion. Farbe Firma, a WHO-GMP certified sterile injectable manufacturer in Gujarat, India producing 100+ injectable products under ISO Class 5 aseptic conditions and exporting to 30+ countries, approaches Israel with that full picture rather than an optimistic one.
Key Takeaways
Israel's medicines regulator is the Ministry of Health's Pharmaceutical Division, working with the Institute for Standardization and Control of Pharmaceuticals (ISCP) in Jerusalem, under the Pharmacists Ordinance (New Version) 1981, the Pharmacists Regulations (Preparations) 1986 and the Good Manufacturing Practice Regulations 2008, with operational detail in Ministry Circular 08/2012. The statutory decision period is 270 days from filing, excluding clock stops, and initial registration runs five years. The registration holder must be an Israeli resident or Israeli-registered corporation — an overseas manufacturer cannot hold the registration directly — and applications are filed through a licensed Israeli pharmacist, with a qualified person for pharmacovigilance appointed and serious adverse events reportable within 15 days.
The reliance reform of 23 March 2025 is the single most important commercial fact about this market, and it cuts both ways. Track A gives a 70-working-day decision for originals and biosimilars registered by at least two recognized authorities within three years; Track B gives 120 working days for one authority within five years; Track C gives 120 working days for generics of innovative medicines already registered in Israel. The recognized authorities are the US FDA, EMA, UK MHRA, Health Canada, Swissmedic and the TGA. India's CDSCO is not among them, and Israel's Certificate of Pharmaceutical Product requirement also specifies a recognized country, so a CDSCO-issued CPP does not satisfy it. The 2025 reform did open a dedicated pathway for first-time registration of generics not yet registered anywhere else — that is the door an Indian manufacturer would use — but its operative procedure is published in Hebrew only and must be confirmed with the Ministry before any commercial commitment.
Israel's GMP bar is higher than a typical emerging market, and treating it otherwise wastes everyone's time. Israel has been a PIC/S participating authority through the ISCP since January 2009, and under the EU-Israel Agreement on Conformity Assessment and Acceptance of Industrial Products, whose pharmaceutical annex entered into force on 19 January 2013, Israel aligned its GMP standards, inspection procedures and forms to those used in the European Union, with mutual recognition of inspection conclusions and of batch certification without re-testing at import. Israeli law also treats the importer as a manufacturer, so the local partner must hold a manufacturer/importer authorization and perform a qualified-person-equivalent release. In practice an overseas sterile injectable site should expect EU-GMP or PIC/S-standard expectations in substance, including EU GMP Annex 1 for sterile manufacture — we present that as a well-founded expectation rather than a published Israeli rule, because the Ministry does not publish an English-language policy on which foreign GMP certificates it accepts.
Documentation is genuinely easier here than in most of this series. Israel deposited its accession to the 1961 Hague Apostille Convention on 11 November 1977, in force from 14 August 1978, and India's accession entered into force on 14 July 2005; Israel raised no objection to India's accession, so the Convention applies between the two countries. Indian Certificates of Pharmaceutical Product, GMP certificates, free-sale certificates and powers of attorney to the Israeli registration holder therefore need only a Ministry of External Affairs apostille, with no Israeli consular legalization. Labelling is the offsetting cost: packaging must carry both English and Hebrew, and the patient information leaflet must be provided in both Hebrew and Arabic.
Introduction: Why an Injectable Manufacturer in Israel Must Meet Global Standards
Israel crossed 10 million residents for the first time in January 2026, with the Central Bureau of Statistics recording 10.178 million people, roughly 13% of them aged 65 or over. It is a high-income, universally insured market where every resident belongs to one of four health funds — Clalit at around 52%, Maccabi around 25%, Meuhedet around 14% and Leumit around 9% — under the National Health Insurance Law enacted in 1994 and in force from January 1995. An injectable manufacturer in Israel is therefore not selling into a fragmented private market but into four large, sophisticated institutional buyers operating under price ceilings benchmarked to Western European reference countries. Health spending runs at 7.6% of GDP against an OECD average of 9.3%, and Israel's per-capita spend on medicines is among the lowest in the developed world. Margin discipline matters more here than volume optimism.
Farbe Firma Pvt Ltd, operating from Gujarat, India as a WHO-GMP certified sterile injectable manufacturer, produces more than 100 injectable formulations inside ISO Class 5 aseptic filling suites and exports to more than 30 countries under CTD and ACTD dossier formats. We approach Israel with a clear-eyed view of what it demands: a full national registration route because India's CDSCO is not a recognized authority under Israel's reliance tracks, an Israeli registration holder filing through a licensed Israeli pharmacist, GMP evidence that will satisfy a PIC/S-member inspectorate whose standards are EU-aligned by treaty, and bilingual and trilingual labelling obligations. What Israel gives back is a straightforward apostille route for Indian documents, a documented and quantified drug-shortage problem, and a reimbursement system that has been putting real money behind oncology.
What Sets a World-Class Injectable Manufacturer in Israel Apart
Any credible injectable manufacturer in Israel has to be honest about which door it is walking through. Israel's March 2025 reliance reform created genuinely fast tracks — 70 or 120 working days — but access depends on prior approval by the US FDA, EMA, UK MHRA, Health Canada, Swissmedic or Australia's TGA, and India's CDSCO is not on that list. Israel's import authorization requirements separately specify a Certificate of Pharmaceutical Product issued within the past two years by a recognized country, which a CDSCO-issued CPP does not satisfy, and biosimilars are explicitly not approved unless already approved by the FDA or EMA. Against that, the same 2025 reform introduced a dedicated pathway for first-time registration in Israel of generics not yet registered elsewhere in the world, together with Ministry Guideline 86/02 from April 2025 allowing prioritization based on unmet medical need and cost savings for the health funds. That combination is the realistic route, and the operative procedure is published in Hebrew only — which is precisely why local regulatory counsel is not optional in this market.
The commercial architecture is equally distinctive. Israel has no classic single national medicines tender; instead, price negotiation with the Ministry of Health as part of health-basket inclusion functions as the de facto procurement mechanism. The Public Committee for the Expansion of the Health Services Basket meets annually and decides what the four health funds must provide. For 2026 the committee had a total additional budget of NIS 650 million, roughly USD 208 million, against more than 600 submitted drugs and technologies requesting around NIS 5 billion — about 13% of requested value was funded, and oncology alone took NIS 337 million, or 52% of the entire expansion. Prices for innovative products without generic competition are capped at the average of the three lowest prices across a basket of European reference countries, generic prices are supervised with increases requiring Ministry approval, and pharmacists may substitute a cheaper generic whenever the prescriber did not write a brand name.
Quality Systems Behind Every Batch We Ship to Israel
Every batch leaving Farbe Firma's Gujarat facility for Israel passes through the same analytical panel we apply globally. Identity, assay and related-substance testing run on validated HPLC and GC methods benchmarked against USP, BP, IP and EP monographs, Karl Fischer titration confirms residual moisture in lyophilized and powder-fill products, and every sterile lot undergoes sterility testing and bacterial endotoxin (LAL) testing, alongside sub-visible particulate counts, pH, osmolality and fill-volume verification. Israel raises the stakes on this documentation in a specific way: because Israeli law treats batch import and release as a manufacturing activity, the Israeli importer's responsible pharmacist performs a qualified-person-equivalent release, so a dossier has to satisfy that individual's scrutiny and the ISCP's separate quality certification, not merely our own quality assurance function.
Stability data is generated under ICH Q1A(R2) long-term and accelerated conditions with photostability assessed per ICH Q1B, supporting shelf-life claims across Israel's Mediterranean and arid climate zones. Because Israel is a PIC/S member and its GMP standards, inspection procedures and forms are EU-aligned under the ACAA, we prepare for EU GMP expectations in substance, including Annex 1 for sterile manufacture, rather than assuming a WHO-GMP certificate alone will carry a foreign site. Israel also enforces the full distribution chain: import authorization will not issue unless the product was transported and stored exclusively by authorized dealers in recognized countries, which has direct consequences for cold-chain design and freight routing on injectables. On documentation, the apostille route between India and Israel is clean, which removes one of the more common sources of delay.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Israel for Global Buyers
The demand case in Israel rests on documented facts rather than optimism. A peer-reviewed study in the Israel Journal of Health Policy Research, published in March 2024, found that drug shortages in Israel rose 2.66-fold between 2014 and 2022, totalling 3,228 shortages of which 79.5% were operational rather than commercial, with the average duration of intermittent shortages lengthening from 85 to 133 days and manufacturers giving the Ministry of Health only 22 days of advance notice on average. Nervous-system drugs, alimentary-tract and metabolism products and dermatologicals led the 2022 shortage categories. Alongside that, Israel's cancer burden is substantial — 30,035 new tumour cases and 11,752 cancer deaths were registered in 2020, the most recent published year — and the 2026 health basket committee put 52% of its entire expansion budget into oncology. For a sterile injectable manufacturer, the honest pitch into this market is supply reliability and continuity, not price alone.
For manufacturers and brand owners, Farbe Firma also functions as a CDMO/CMO partner, offering private-label sterile injectables built on the same WHO-GMP, ISO Class 5 platform with CTD-format technical files. There is a genuine structural gap worth naming. Israel is home to Teva Pharmaceutical Industries, one of the world's largest generic manufacturers and the largest company on the Israeli market by market value — yet Israel accounts for only around 2% of Teva's global revenues and roughly 8% of its total global production. Hosting a generics giant has not made Israel self-sufficient; the domestic market is small, price-capped and supplied largely from Switzerland, the Netherlands, Belgium and the United States. Ministry of Health registration conditions can also impose regular and ongoing supply obligations on a registration holder, which is a live commitment rather than boilerplate — and it favours manufacturers with genuine capacity depth.
India's pharmaceutical presence in Israel today is real but modest, and it would be misleading to describe it otherwise. UN Comtrade records Israel importing about USD 26.89 million of pharmaceutical products from India in 2025 — roughly 1.2% of Israel's approximately USD 2.2 billion of imports from India that year — of which the specifically sterile pharmaceutical goods line was under half a million dollars. The recognized-authority and CPP requirements described above are the most plausible explanation for that gap. The bilateral relationship is nonetheless moving: India and Israel signed terms of reference for free trade agreement negotiations in November 2025, with the first round concluding in New Delhi in February 2026 and the second in July 2026, alongside a bilateral investment treaty signed in September 2025. One caution matters more than the rest: a free trade agreement addresses tariffs, not the Pharmacists Regulations, the recognized-authority list or the CPP requirement. Regulatory access and tariff access are separate problems, and only the smaller one is on the negotiating table. Farbe Firma builds every Israel engagement around that distinction.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer for Israel?
Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer based in Gujarat, India, operating ISO Class 5 aseptic filling lines and producing more than 100 injectable products for export to over 30 countries, with documentation prepared in CTD and ACTD formats. We would add one honest qualification for Israel specifically: because Israel has been a PIC/S member since 2009 and aligned its GMP standards to the European Union under the EU-Israel ACAA in force since 2013, an overseas sterile site should expect EU-GMP or PIC/S-standard evidence and inspection expectations rather than assuming a WHO-GMP certificate alone will be sufficient.
How does injectable product registration work in Israel?
The Ministry of Health's Pharmaceutical Division registers medicines under the Pharmacists Ordinance 1981 and the Pharmacists Regulations (Preparations) 1986, with quality certification from the Institute for Standardization and Control of Pharmaceuticals. The statutory decision period is 270 days excluding clock stops, and initial registration lasts five years. A March 2025 reform created reliance tracks of 70 or 120 working days for products already approved by the FDA, EMA, MHRA, Health Canada, Swissmedic or the TGA. India's CDSCO is not a recognized authority, so a product approved only in India uses the full national route, and the 2025 reform's dedicated pathway for generics not registered elsewhere is the relevant door — its operative procedure is published in Hebrew only and should be confirmed with the Ministry.
Do we need a local partner to sell injectables in Israel?
Yes, and more so than in most markets. The registration holder must be an Israeli resident or a corporation registered in Israel, the application must be filed through a licensed Israeli pharmacist, and a qualified person for pharmacovigilance must be appointed. Israeli law also treats the importer as a manufacturer, so the local partner needs a manufacturer/importer authorization and a responsible pharmacist performing a qualified-person-equivalent batch release. Commercially, the four health funds — Clalit, Maccabi, Meuhedet and Leumit — together with hospitals are the real buyers, and health-basket inclusion is what converts a registration into national volume.
Which injectables are in strongest demand in Israel?
Oncology is the clearest signal: the 2026 health basket committee allocated NIS 337 million to oncology, 52% of its entire NIS 650 million expansion, against a cancer burden of 30,035 new cases registered in 2020. Beyond that, Israel's documented shortage profile points to specific gaps — nervous-system drugs accounted for 18% of 2022 shortages, alimentary-tract and metabolism products 14%, and dermatologicals 11% — with 79.5% of shortages operational rather than commercial, meaning supply reliability rather than price is the binding constraint. An ageing population, with about 13% of Israelis aged 65 or over, supports steady critical-care and hospital injectable demand.
What documentation and logistics considerations matter most for an Israel launch?
Documentation legalization is straightforward: Israel joined the Hague Apostille Convention with effect from August 1978 and India from July 2005, with no objection between them, so Indian Certificates of Pharmaceutical Product, GMP certificates and powers of attorney need only a Ministry of External Affairs apostille. The harder requirements are elsewhere. A Certificate of Pharmaceutical Product must come from a recognized country, packaging must be in both English and Hebrew, and the patient information leaflet must be in both Hebrew and Arabic. Import authorization will not issue unless the product was transported and stored exclusively by authorized dealers in recognized countries, so cold-chain routing must be designed for that rule from the start.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments